Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Meta-analysis: Pioglitazone reduces ischemic cardiovascular risk in diabetes patients

Sep. 20, 2007

FDA accepts Samaritan's IND for SP-6300 in Cushing's syndrome

Sep. 20, 2007

MicroIslet and Progenitor sign manufacturing agreement for MicroIslet-P

Sep. 20, 2007

Recent patents report new therapeutic agents for disorders associated with impaired metabolism

Sep. 19, 2007

Positive tesofensine results from NeuroSearch TIPO-1 study in obesity

Sep. 19, 2007

Asubio Pharma acquires exclusive rights to Kuvan NDA data for filing in Japan

Sep. 19, 2007

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Sep. 18, 2007

Positive results for Novo Nordisk phase III trial of human GLP-1 analogue liraglutide

Sep. 18, 2007

Radius grants Novartis worldwide license option for BA-058 for osteoporosis

Sep. 18, 2007

Update on Quigley's phase IIb study of QR-333 for diabetic peripheral neuropathy

Sep. 18, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...